Drug Interaction:
Drug Interaction- summary-
+ Iobenguane I 123
Antidepressants eg. amitriptyline, imipramine , SSRIs
Antihypertensives eg reserpine, labetalol
Cocaine
Sympathomimetic amines eg. ephedrine, phenylephrine, pseudoephedrine
drugs that interfere with norephinephrine may decrease the uptake of iobenguane in
neuroendocrine tumors and lead to false -negative imaging results. When feasible
stop these drugs before logenguane administration ( for atleast 5 biological half-lives)
and monitor patients for occurrence of clinically significant withdrawal symptoms,
especially patients with elevated levels of circulating catecholamine and their
metabolites
Indication:
Detection of pheochromocytoma/neuroblastoma
Adverse Reaction:
Adverse reactions are mild to moderate
dizziness, flushing, injection site reactions, hemorrhage, pruritus or rash
Contra-Indications:
Knownhypersensitivity to the drug
Special Precautions/Warnings-
Concomittant thyroid accumulation - failure to block thyroid uptake of iodine 123 may
result in an increased long-term risk for thyroid neoplasia.
Administer thyroid blocking medications before iobenguane 1 123 administration
Hypertension- prior to iobenguane 1 123 administration ensure emergency cardiac
and antihypertensive treatments are readily available,
Hypersensitivity - have anaphylactic and hypersentivity treatment measures available
prior to iobguane 1 123 administration
Renal function impairment - Iboguane I 123 safety and efficacy have not been established
in these patients
Pregnancy - give Iobuguane I 123 to a pregnant women only if clearly needed
Lactation- consider interrupting breast feeding for 6 days after iobeguane I 123
administration in order to minimise risks to breast- feeding infants
Children- safety and effectivness in 1 month to 16 years of age have not been studied
Elderly - consider assesssment of renal function in elderly patients prior to
iobenguane administration
Dosages/ Overdosage Etc:
Indication-
Detection of pheochromocytoma/neuroblastoma
Dosage-
10mCi ( 370 MBq )
Patient Information:
Ref - USP PDI Vol II 17th Edition (1997)
1.Pregnancy-
This radiopharmaceutical is not recommended for use during pregnancy.
This is to avoid exposing the fetus to harmful effects of radiation.
2. Breast-feeding-
If you receive radioiodinated iobenguane, it must be necessary to stop breast
feeding after receiving it. Discuss this with your doctor.
3.Children and adolescents-
Children and adolescents are especially sensitive to the effects of radiation.
This may increase the chance of side effects during treatment. Discuss this
with your doctor.
4.Older adults-
Radioioddinated iobenguane has been used in older people and has not
caused different side effects or problems in older people than in younger
adults.
5. Other medicines-
Tell your doctor if you are using any of the following medicines
Amphetamine or
Calcium channel blockers or
Cocaine or
Haloperidol or
Labetolol or
Loxapine or
Reserpine or
Tricyclic antidepressants - these medicines may keep the affected organs
or tissue from getting the amount of radioactive iobenguane it need to fight the
disease
6. Other medical problems-
Make sure you tell your doctor if you have any other medical problems
Pregnancy and lactation:
Pregnancy -
Give Iobuguane I 123 to a pregnant women only if clearly needed
Lactation-
Consider interrupting breast feeding for 6 days after iobeguane I 123
administration in order to minimise risks to breast- feeding infants
Children-
Safety and effectivness in 1 month to 16 years of age have not been studied
Elderly -
Consider assesssment of renal function in elderly patients prior to
iobenguane administration
Manufacturer Details